TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02189902

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4000 IU/d D3 over 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 7000 IU/d D3 over 12 weeks
Study: NCT00925405

Intervention type: PROCEDURE
Intervention: Breast MRI
Description: Magnetic resonance imaging (MRI) scans of the breasts once per year

Intervention type: PROCEDURE
Intervention: Mammogram
Description: Breast x-ray used to detect breast cancer and look for abnormalities in the breast.
Study: NCT02162680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bacteriostatic normal saline (BNS)
Study: NCT03468166

Intervention type: OTHER
Intervention: Chronic stroke
Description: The data for motor function and gait pattern analysis was obtained.
Study: NCT04060277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Given as SOC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letermovir
Description: Given as SOC
Study: NCT03823222

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Duckweed protein
Description: 20 grams isolated protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: 20 grams isolated protein
Study: NCT01423214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted surgery
Description: da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery
Description: Conventional laparoscopic procedures
Study: NCT04587128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Epidermal growth factor receptor inhibitor, anti-neoplastic
Study: NCT04060277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Description: Given IM
Study: NCT04587128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Epidermal growth factor receptor inhibitor, anti-neoplastic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Epidermal growth factor receptor inhibitor, anti-neoplastic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Epidermal growth factor receptor inhibitor, anti-neoplastic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Epidermal growth factor receptor inhibitor, anti-neoplastic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Epidermal growth factor receptor inhibitor, anti-neoplastic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: anti-neoplastic, chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: folinic acid (also called leucovorin, calcium folinate or FA) fluorouracil (also called 5FU) irinotecan given per institutional standard (intravenously day 1 and day 15 of 28 day cycle) alternating and not concomitant with panitumumab or cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (or biosimilar) may be administered with FOLFIRI per treating MD discretion and will be given per institutional standard (5 mg/kg intravenously day 1 and day 15 of 28 day cycle)
Study: NCT04060277

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given IM
Study: NCT02739347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Trans-cranial direct-current stimulation
Description: Active stimulation group will receive 20 min of 2 mA direct current stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Trans-cranial direct current stimulation
Description: This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
Study: NCT04538365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triclosan 0.5 % Topical Solution
Description: Hand antisepsis by scrub Surgical Hand scrubbing using triclosan 0.5% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propanolol
Description: Hand antisepsis by scrub Surgical Hand scrubbing using Propanolol 60% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
Study: NCT02809144

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nerve block
Description: Nerve block: 31 ml ropivacaine 7.5 mg/ml (Lateral sagittal infraclavicular brachial plexus block) + 4 ml ropivacaine 5 mg/ml (suprascapular nerve block) + 5 ml ropivacaine 5 mg/ml (superficial cervical plexus block)
Study: NCT00705302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group training with self-help group
Description: Combined educational and exercise program for pulmonary rehabilitation, with (1) or without(2 a self-help group. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group. Patients will instead of five of the group training sessions, participate in a self-help group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group training
Description: Combined educational and exercise program for pulmonary rehabilitation. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group.
Study: NCT03124199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin 400 mg/8 h added to the standard triple therapy
Study: NCT00704301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Rivastigmine, two times 1,5 mg a day. The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 times a day
Study: NCT01146132

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Conventional diet +/- wine
Description: usual eating habits

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Luxembourg variant of Mediterranean diet + physical activity +/- wine
Description: Walnuts, almonds, mustard and soy bean products as part of the Indo-Mediterranean diet could be recommended to ensure a variety of food constellation, as well as dark chocolate. This form of diet will be addressed to as Luxembourg variant of the Mediterranean diet

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Luxembourg variant of Mediterranean diet + physical activity +/- wine
Description: Walnuts, almonds, mustard and soy bean products as part of the Indo-Mediterranean diet could be recommended to ensure a variety of food constellation, as well as dark chocolate. This form of diet will be addressed to as Luxembourg variant of the Mediterranean diet
Study: NCT03422146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tea Tree Oil (TTO)
Description: Participants will use the Cliradex® eyelid hygiene lid wipe / towelette for BID for 2 weeks
Study: NCT03844243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGF
Description: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGF
Description: Intramuscular injection
Study: NCT03422146

Intervention type: OTHER
Group type: OTHER
Intervention: I-Lid'n Lash® Hygiene
Description: Patients will use the I-Lid'n Lash® Hygiene lid wipe / towelette for BID for 2 weeks
Study: NCT03863678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopemental therapy (NDT)
Description: NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopemental therapy (NDT) and dry needling
Description: NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions). Dry needling will be applied on M. Gastrocnemius, M.Quadriceps, M.Flexor Carpi Radialis, and M.Biceps Brachii muscles, 60 seconds (sec) for each muscle groups at the end of the NDT treatment.
Study: NCT04509973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: ATC code: H02AB02

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: ATC code: H02AB02
Study: NCT00993057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Adjustable insulin infusion scale with loading doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Adjustable insulin infusion scale with loading doses
Study: NCT03616613

Intervention type: DIAGNOSTIC_TEST
Intervention: ABDOMINAL DUPLEX ULTRASONOGRAPHY
Description: Abdominal ultrasonography performed by both primary care doctors or vascular surgeons in Hospital de la Santa Creu i Sant Pau area

Intervention type: DIAGNOSTIC_TEST
Intervention: ABDOMINAL DUPLEX ULTRASONOGRAPHY
Description: Abdominal ultrasonography performed by both primary care doctors or vascular surgeons in Hospital de la Santa Creu i Sant Pau area
Study: NCT00133770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole
Description: The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
Study: NCT02254148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: single dose of midazolam given as oral solution (day 1 of visits 2 and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine
Description: single dose of caffeine given as tablets (day 1 of visits 2 and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: single dose of digoxin given as tablets (day 3 of visits 2 and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: single dose of warfarin given as tablets (day 1 of visits 2 and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: single dose of omeprazole given as tablet (day 1 of visits 2 and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: multiple doses of BI 187004 given as tablets (day 7-12 of visit 2 and day 1-6 of visit 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Description: single dose of metoprolol given as tablets (day 1 of visits 2 and 3)
Study: NCT01817348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lidocaine group
Description: * Patient position: prone position with arm under the abdomen and the elbow flexed to a right angle~* Injection with a 25-gauge, 1.5-inch long needle fitted with 3ml syringe filled with 3ml 1% lidocaine.
Study: NCT03844243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic-saline
Description: Intramuscular injection
Study: NCT01794182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide for Injection
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT02229279

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Teleconsulting
Study: NCT04335409

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: The patients are asked to complete a questionnaire (paper version) once a week during the period of radiotherapy and up to 24 weeks following radiotherapy. In this questionnaire, the patients are asked to state and rate their symptoms potentially associated with pneumonitis. Scoring points are assigned to the severity of the symptoms (symptom scores), and the resulting sum score (patient score) will be used for identification of radiation pneumonitis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: In 10 patients, the paper version of the symptom-based scoring system (questionnaire) will be supplemented by a mobile application (app) asking the same questions regarding symptoms potentially associated with pneumonitis.
Study: NCT01817348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy (PT)
Description: - Include electric therapy, hot pack, followed by stretch exercise and joint mobilization

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy (PT)
Description: - Include electric therapy, hot pack, followed by stretch exercise and joint mobilization
Study: NCT03734302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole , mutiple dose /oral/empty stomach
Study: NCT01928602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TherAppy Language App
Description: Language TherAppy combines the receptive exercises of Comprehension TherAppy and Reading TherAppy with the expressive training of Naming TherAppy and Writing TherAppy. The app uses the same core functional vocabulary (nouns, verbs, \& adjectives) and over 700 clear pictures. Each app tracks data, sends professional e-mailed reports, and has built-in levels, cues, and options.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TherAppy Language App
Description: Language TherAppy combines the receptive exercises of Comprehension TherAppy and Reading TherAppy with the expressive training of Naming TherAppy and Writing TherAppy. The app uses the same core functional vocabulary (nouns, verbs, \& adjectives) and over 700 clear pictures. Each app tracks data, sends professional e-mailed reports, and has built-in levels, cues, and options.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Games
Description: A mind-game app is said to improve brain functioning at any age. The chosen app will give feedback such as score history, and progress reports. Tasks will focus on attention, memory spatial awareness and executive function.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Games
Description: A mind-game app is said to improve brain functioning at any age. The chosen app will give feedback such as score history, and progress reports. Tasks will focus on attention, memory spatial awareness and executive function.
Study: NCT03659916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250 (odevixibat)
Description: A4250 is a small molecule and selective inhibitor of IBAT
Study: NCT03118492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glycosylated Recombinant Human G-CSF AVI-014
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT01773564

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Current hospital dressing
Description: Patients were assigned to either arm following a randomization scheme 1:1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ IV Advanced Securement dressing
Description: Patients were assigned to either arm following a randomization scheme 1:1.
Study: NCT01580761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: 14 days of sleep restriction, 4 hours of sleep per day.
Study: NCT00352495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine sulfate
Study: NCT00885690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertindole
Description: Sertindole 16-24 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine 10-20 mg
Study: NCT03586336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReDS-Guided
Description: ReDS measurements will be shared with the treating clinicians who can use the information to guide diuresis and determine the appropriate timing of discharge

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: ReDS measurements will not be shared with the treating clinicians, who will guide diuresis using standard clinical criteria
Study: NCT04319666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left main stenting with intravascular lithotripsy
Description: Intravascular lithotripsy (IVL) will be used to modify coronary artery calcification prior to stent implantation in left main coronary disease. Intravascular ultrasound (IVUS) will be used pre and post IVL and post stenting.
Study: NCT04350567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Description: On the first night, the participant sleeps normally as we assess their melatonin through blood work. On the second night, the participant has 3 PET/MRI scans. On the third night, the participant undergoes sleep deprivation. On the fourth night, the participant sleeps normally and we assess their melatonin again through blood work. Depression scores are taken before and after the intervention.
Study: NCT01782872

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Block (ISB) - 0.375% Ropivacaine + additives
Description: Ultrasound-guided single-injection ISB: ropivacaine 0.375% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous (IV): saline

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Block (ISB) - 0.2% Ropivacaine + additives
Description: Ultrasound-guided single-injection ISB: ropivacaine 0.2% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous: saline

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Block (ISB) - 0.1% Ropivacaine + additives
Description: Ultrasound-guided single-injection ISB: ropivacaine 0.1% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous: saline

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Block (ISB) - Systemic Control
Description: Ultrasound-guided single-injection ISB: ropivacaine 0.375%; Intravenous: clonidine (100 mcg) + dexamethasone (4 mg) + buprenorphine (150 mcg)
Study: NCT05731089

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification with IVI of aflibercept
Description: IVI was either before or after cataract surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification with IVI of aflibercept
Description: IVI was either before or after cataract surgery
Study: NCT01403025

Intervention type: DRUG
Intervention: liraglutide
Description: Once daily at a fixed timing, and subcutaneously (under the skin) in the abdomen, in the thigh or in the upper arm
Study: NCT02150720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1g intra-articular before closing the wound surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Description: 5mL intra-articular before closing the wound surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocauterization
Description: Coagulation blood from vessels by means of a electrocautery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocauterization
Description: Coagulation blood from vessels by means of a electrocautery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocauterization
Description: Coagulation blood from vessels by means of a electrocautery.
Study: NCT00570024

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Acupuncture
Description: In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: AA
Description: In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
Study: NCT03552302

Intervention type: BEHAVIORAL
Intervention: Yoga
Description: 1. Yoga stretch warm-up exercise for 15 minutes.~2. Five kinds of yoga correction method for 30 minutes (abdominal breathing, throat breathing, wind box breathing, nasal alternating breathing, buzzing breathing).~3. Great rest for 15 minutes
Study: NCT04230057

Intervention type: DIETARY_SUPPLEMENT
Intervention: Antitumor B
Description: Single dose 2400 mg
Study: NCT03627039

Intervention type: DRUG
Intervention: SGLT2
Description: All SGLT2 medications approved prior to 2017 will be included (Canagliflozin, empagliflozin, dapagliflozin (all doses, all of the medications are oral)

Intervention type: DRUG
Intervention: Metformin
Description: Metformin is the main comparator of interest. In a secondary analysis GLP1 will be the comparator
Study: NCT00369538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan, hydrochlorothiazide
Description: Two administrations of losartan per day,up to 100mg per day, during 2 months, followed by a wash-out during 1 month, and then one administration of hydrochlorothiazide, 25 mg per day during 2 months